Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

NKTX Nkarta

Not Yet Opened 12-08 16:00:00 EST

1.83

+0.03

+1.67%

盘后1.83

+0.000.00%

19:55 EST

High1.85	Low1.78	Vol504.98K
Open1.83	D1 Closing1.80	Amplitude3.89%
Mkt Cap129.98M	Tradable Cap96.09M	Total Shares71.03M
T/O916.16K	T/O Rate0.96%	Tradable Shares52.51M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"NKTX","market":"US","secType":"STK","nameCN":"Nkarta","latestPrice":1.83,"timestamp":1765227600000,"preClose":1.8,"halted":0,"volume":504982,"hourTrading":{"tag":"盘后","latestPrice":1.83,"preClose":1.83,"latestTime":"19:55 EST","volume":127663,"amount":233623.81,"timestamp":1765241707195},"delay":0,"floatShares":52510907,"shares":71029512,"eps":-1.388699,"marketStatus":"Not Yet Opened","change":0.03,"latestTime":"12-08 16:00:00 EST","open":1.83,"high":1.85,"low":1.78,"amount":916158.190193,"amplitude":0.038889,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.388699,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765270800000},"marketStatusCode":0,"adr":0,"listingDate":1594353600000,"exchange":"NASDAQ","adjPreClose":1.8,"preHourTrading":{"tag":"盘前","latestPrice":1.84,"preClose":1.8,"latestTime":"09:27 EST","volume":415,"amount":763.134536,"timestamp":1765204057223},"postHourTrading":{"tag":"盘后","latestPrice":1.83,"preClose":1.83,"latestTime":"19:55 EST","volume":127663,"amount":233623.81,"timestamp":1765241707195},"volumeRatio":0.662185,"impliedVol":0.5069,"impliedVolPercentile":0.1968},"requestUrl":"/m/hq/s/NKTX","defaultTab":"news","newsList":[{"id":"2588030269","title":"Nkarta to Join Evercore Healthcare Conference in Miami","url":"https://stock-news.laohu8.com/highlight/detail?id=2588030269","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2588030269?lang=en_us&edition=fundamental","pubTime":"2025-12-02 20:09","pubTimestamp":1764677379,"startTime":"0","endTime":"0","summary":"Nkarta Inc. will participate in the Evercore 8th Annual Healthcare Conference on December 4, 2025. The event will feature a fireside chat at 10:50 a.m. ET, with a live webcast and a replay available on the Investors section of Nkarta's website for approximately 90 days.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. nkarta Inc. published the original content used to generate this news brief via GlobeNewswire  on December 02, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251202:nNDLbbvwTg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BGHQF748.EUR","LU2210149790.SGD","NKTX","LU2210150020.SGD","BK4588","BK4505","IE00B3QW5Z07.USD","BK4127","LU0314104364.USD","LU2095319765.USD","BK4585","BK4139","EVR","IE00B64PRP62.GBP","NDAQ","BK4112","IE00BKPKM429.USD"],"gpt_icon":0},{"id":"2584921605","title":"Nkarta Q3 EPS USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2584921605","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584921605?lang=en_us&edition=fundamental","pubTime":"2025-11-20 01:15","pubTimestamp":1763572542,"startTime":"0","endTime":"0","summary":"Nov 10 (Reuters) - Nkarta Q3 net income USD -21.715 million.:  ((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))  Source Date/Time = 10-NOV-202521:01:45.973 GMT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251119:nRSD6q2SDD:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4139","BK4505"],"gpt_icon":0},{"id":"2582739366","title":"Nkarta Is Maintained at Buy by Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2582739366","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582739366?lang=en_us&edition=fundamental","pubTime":"2025-11-12 00:13","pubTimestamp":1762877580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/NKTX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 11:13 ET (16:13 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","SF"],"gpt_icon":0},{"id":"2582369747","title":"Nkarta price target lowered to $11 from $12 at Stifel","url":"https://stock-news.laohu8.com/highlight/detail?id=2582369747","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582369747?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:45","pubTimestamp":1762865127,"startTime":"0","endTime":"0","summary":"Stifel lowered the firm’s price target on Nkarta (NKTX) to $11 from $12 and keeps a Buy rating on the shares. The firm believes management’s decisi...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nkarta-price-target-lowered-to-11-from-12-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nkarta-price-target-lowered-to-11-from-12-at-stifel-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX","SF"],"gpt_icon":0},{"id":"2582352737","title":"Nkarta’s Strategic Management and Financial Strength Justify Buy Rating and $10 Target Price","url":"https://stock-news.laohu8.com/highlight/detail?id=2582352737","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582352737?lang=en_us&edition=fundamental","pubTime":"2025-11-11 17:55","pubTimestamp":1762854916,"startTime":"0","endTime":"0","summary":"Needham analyst Gil Blum maintained a Buy rating on Nkarta today and set a price target of $10.00. Gil Blum has given his Buy rating due to a combi...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/nkartas-strategic-management-and-financial-strength-justify-buy-rating-and-10-target-price-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/nkartas-strategic-management-and-financial-strength-justify-buy-rating-and-10-target-price-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NKTX"],"gpt_icon":0},{"id":"2582594359","title":"Analysts Offer Insights on Healthcare Companies: Nkarta (NKTX), BioLife Solutions (BLFS) and Cardiff Oncology (CRDF)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582594359","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582594359?lang=en_us&edition=fundamental","pubTime":"2025-11-11 16:30","pubTimestamp":1762849820,"startTime":"0","endTime":"0","summary":"Analysts have been eager to weigh in on the Healthcare sector with new ratings on Nkarta (NKTX – Research Report), BioLife Solutions (BLFS – Resear...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-biolife-solutions-blfs-and-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-nkarta-nktx-biolife-solutions-blfs-and-cardiff-oncology-crdf-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LABU","BK4137","BK4139","LU1169589451.USD","BK4198","NKTX","XBI","BK4505","BK4121","BK4585","BK4588","LU0029874061.USD","XLV","LU0128526141.USD","LU1169590202.USD","HCSG","BLFS","CRDF","BK4581"],"gpt_icon":0},{"id":"2582399173","title":"Nkarta Advances NKX019 Program Amid Financial Stability","url":"https://stock-news.laohu8.com/highlight/detail?id=2582399173","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582399173?lang=en_us&edition=fundamental","pubTime":"2025-11-11 12:14","pubTimestamp":1762834496,"startTime":"0","endTime":"0","summary":"Nkarta, Inc. ( ($NKTX) ) has released its Q3 earnings. Here is a breakdown of the information Nkarta, Inc. presented to its investors. Nkarta, Inc....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nkarta-advances-nkx019-program-amid-financial-stability?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nkarta-advances-nkx019-program-amid-financial-stability?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4505","NKTX","BK4139"],"gpt_icon":0},{"id":"2582383286","title":"Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383286","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383286?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:47","pubTimestamp":1762811249,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.35) by 16.43 percent. This is a 25.64 percent increase over losses of $(0.39) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48768047/nkarta-q3-eps-0-29-beats-0-35-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nkarta Q3 EPS $(0.29) Beats $(0.35) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"gpt_icon":0},{"id":"2582807101","title":"BRIEF-Nkarta Q3 EPS USD -0.29","url":"https://stock-news.laohu8.com/highlight/detail?id=2582807101","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582807101?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808505,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Q3 EPS USD -0.29\n\n\nNov 10 (Reuters) - Nkarta Q3 net income USD -21.715 million.\n\nQ3 basic EPS USD -0.29\nQ3 cash & investments USD 316.5 million","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nPLXC859BB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4505","BK4139"],"gpt_icon":0},{"id":"2582383513","title":"Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383513","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383513?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:01","pubTimestamp":1762808460,"startTime":"0","endTime":"0","summary":"Enrollment now underway in second dose-escalation cohortDeep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide v","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/11/10/3185023/0/en/Nkarta-Reports-Third-Quarter-2025-Financial-Results-and-Corporate-Highlights.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4230","BK4505","BK4139","BK4022","CAR"],"gpt_icon":0},{"id":"2579120958","title":"Nkarta to Participate in November Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2579120958","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579120958?lang=en_us&edition=fundamental","pubTime":"2025-10-31 01:14","pubTimestamp":1761844440,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Oct.  30, 2025   -- Nkarta, Inc. , a clinical-stage biopharmaceutical company developing engineered natural killer  cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen’s Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta’s website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-shelf natural killer  cell therapies for autoimmune diseases. By combining its cell expansion and cryopreservation platform with proprietary cell engineering technologies and CRISPR-based genome engineering capabilities, Nkarta is building a pipeline of future cell therapies engineered fo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/30/3177788/0/en/Nkarta-to-Participate-in-November-Investor-Conferences.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","BK4139","BK4505"],"gpt_icon":0},{"id":"2578678609","title":"Nkarta, Inc. Advances CAR NK Cell Therapy Study for Immune-Mediated Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2578678609","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578678609?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:58","pubTimestamp":1761595137,"startTime":"0","endTime":"0","summary":"Nkarta, Inc. (($NKTX)) announced an update on their ongoing clinical study. Study Overview: Nkarta, Inc. is conducting a Phase 1 study titled ‘A Ph...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/nkarta-inc-advances-car-nk-cell-therapy-study-for-immune-mediated-diseases?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/nkarta-inc-advances-car-nk-cell-therapy-study-for-immune-mediated-diseases?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4505","NKTX","BK4022","CAR","BK4230"],"gpt_icon":0},{"id":"2577439385","title":"Nkarta Unveils Promising NKX019 Data for B-Cell Depletion in Autoimmune Disease Models","url":"https://stock-news.laohu8.com/highlight/detail?id=2577439385","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577439385?lang=en_us&edition=fundamental","pubTime":"2025-10-22 22:07","pubTimestamp":1761142076,"startTime":"0","endTime":"0","summary":"Nkarta Inc., a clinical-stage biopharmaceutical company, announced that it will present new clinical data on its investigational therapy, NKX019, at the American College of Rheumatology  Convergence 2025 meeting in Chicago. The data to be presented demonstrate that NKX019, an allogeneic off-the-shelf CD19 targeting CAR-NK cell therapy, achieved robust pathogenic B-cell depletion followed by reconstitution of the B cell compartment in participants with non-Hodgkin lymphoma. Preclinical studies also showed that NKX019 effectively depletes pathogenic B cells in in vivo lymphoma models and in vitro autoimmune disease models. The poster presentation is scheduled for Sunday, October 26, 2025, and the abstract is available on the ACR Convergence 2025 website.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and shou","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251022:nNDLkPbLY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BKPKM429.USD","BK4139","IE00B64PRP62.GBP","IE00BGHQF748.EUR","BK4588","NDAQ","NKTX","BK4112","LU2210150020.SGD","LU2210149790.SGD","BK4505","LU2095319765.USD","IE00B3QW5Z07.USD","LU0314104364.USD","BK4585"],"gpt_icon":0},{"id":"2577393959","title":"Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2577393959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577393959?lang=en_us&edition=fundamental","pubTime":"2025-10-22 22:07","pubTimestamp":1761142020,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Oct.  22, 2025  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to tre","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/10/22/3171260/0/en/Nkarta-Announces-Poster-Presentation-at-Upcoming-American-College-of-Rheumatology-ACR-Convergence-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX","AFG","ACR","BK4117","BK4107","BK4110","BK4505","BK4139"],"gpt_icon":0},{"id":"2564804709","title":"Nkarta to Participate in a September Investor Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2564804709","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2564804709?lang=en_us&edition=fundamental","pubTime":"2025-09-02 20:01","pubTimestamp":1756814460,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2025  (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, toda","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/09/02/3142645/0/en/Nkarta-to-Participate-in-a-September-Investor-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4505","NKTX","BK4139"],"gpt_icon":0},{"id":"2559622565","title":"Nkarta Inc reports results for the quarter ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2559622565","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559622565?lang=en_us&edition=fundamental","pubTime":"2025-08-13 05:30","pubTimestamp":1755034246,"startTime":"0","endTime":"0","summary":"Nkarta Inc reports results for the quarter ended June 30 - Earnings SummaryNkarta Inc NKTX.OQ reported a quarterly adjusted loss of 31 cents per share for the quarter ended June 30, higher than the sa","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nL8N3U42A4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"gpt_icon":0},{"id":"2559510621","title":"Nkarta Q2 EPS $(0.31) Beats $(0.37) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2559510621","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559510621?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:16","pubTimestamp":1755029814,"startTime":"0","endTime":"0","summary":"Nkarta (NASDAQ:NKTX) reported quarterly losses of $(0.31) per share which beat the analyst consensus estimate of $(0.37) by 15.3 percent. This is a 8.82 percent increase over losses of $(0.34) per share from the same","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/08/47074533/nkarta-q2-eps-0-31-beats-0-37-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Nkarta Q2 EPS $(0.31) Beats $(0.37) Estimate","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NKTX"],"gpt_icon":0},{"id":"2559629129","title":"Nkarta Inc. Reports Q2 2025 Net Loss of $23M, EPS of $0.31; Cash Reserves Expected to Fund Operations Through 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2559629129","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559629129?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:03","pubTimestamp":1755028986,"startTime":"0","endTime":"0","summary":"Nkarta, Inc. , a clinical-stage biopharmaceutical company, reported its financial results for the second quarter of 2025. The company recorded a net loss of $23.0 million, translating to $0.31 per basic and diluted share. This loss includes non-cash charges totaling $3.4 million, primarily from share-based compensation and depreciation expenses. Research and development expenses for the quarter stood at $20.8 million, with non-cash stock-based compensation accounting for $0.9 million of this amount. General and administrative expenses were $6.4 million, including $1.2 million in non-cash stock-based compensation. Nkarta ended the quarter with $334.0 million in cash, cash equivalents, restricted cash, and investments in marketable securities. The company anticipates that this cash position will be sufficient to fund its operations into 2029. Significant corporate updates include the appointment of Shawn Rose, M.D. Ph.D., as Chief Medical Officer and Head of Research and Development. Dr.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nNDL2Gmsqt:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["JNJ","NDAQ","NKTX"],"gpt_icon":0},{"id":"2559629165","title":"BRIEF-Nkarta Q2 Net Income USD -22.977 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2559629165","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559629165?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028905,"startTime":"0","endTime":"0","summary":"BRIEF-Nkarta Q2 Net Income USD -22.977 Million\n\n\nAug 12 (Reuters) - Nkarta Q2 basic EPS USD -0.31.\n\nQ2 cash & investments USD 334 million\nQ2 EPS USD -0.31","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLX26172A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4505","NKTX"],"gpt_icon":0},{"id":"2559762180","title":"Nkarta Inc - Cash Balance of $334 Mln at June 30 to Fund Operations Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2559762180","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2559762180?lang=en_us&edition=fundamental","pubTime":"2025-08-13 04:01","pubTimestamp":1755028860,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250812:nPLX26172A:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4505","NKTX","BK4139"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.nkartatx.com","stockEarnings":[{"period":"1week","weight":0.011},{"period":"1month","weight":-0.0663},{"period":"3month","weight":-0.1159},{"period":"6month","weight":-0.085},{"period":"1year","weight":-0.2907},{"period":"ytd","weight":-0.2651}],"compareEarnings":[{"period":"1week","weight":0.0049},{"period":"1month","weight":0.0189},{"period":"3month","weight":0.0512},{"period":"6month","weight":0.1368},{"period":"1year","weight":0.1247},{"period":"ytd","weight":0.1664}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.101986},{"month":2,"riseRate":0.4,"avgChangeRate":0.003163},{"month":3,"riseRate":0.4,"avgChangeRate":-0.055532},{"month":4,"riseRate":0.6,"avgChangeRate":0.150592},{"month":5,"riseRate":0.2,"avgChangeRate":-0.136477},{"month":6,"riseRate":0.2,"avgChangeRate":-0.109268},{"month":7,"riseRate":1,"avgChangeRate":0.107935},{"month":8,"riseRate":0.333333,"avgChangeRate":-0.06764},{"month":9,"riseRate":0.166667,"avgChangeRate":-0.061634},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.060284},{"month":11,"riseRate":0.5,"avgChangeRate":-0.004483},{"month":12,"riseRate":0.333333,"avgChangeRate":0.309215}],"exchange":"NASDAQ","name":"Nkarta","nameEN":"Nkarta"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Nkarta,NKTX,Nkarta股票,Nkarta股票老虎,Nkarta股票老虎国际,Nkarta行情,Nkarta股票行情,Nkarta股价,Nkarta股市,Nkarta股票价格,Nkarta股票交易,Nkarta股票购买,Nkarta股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Nkarta(NKTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Nkarta(NKTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction